BioSpace

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st, 2026, ...
Finanznachrichten

NeurAxis, Inc.: NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Achieves significant expansion of NeurAxis' total addressable market Clearance now includes patients aged "8 years and older" Expanded age indication will utilize the upcoming January 1 st, 2026, ...
Yahoo Finance

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...